CNS Summit 2014, Boca Raton, FL Ole Voges, Ingo Weigmann, Norman Bitterlich, Christoph Schindler and Christopher Missling View Poster Post navigationPreviousPrevious post:Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer’sNextNext post:Anavex Upgrades to OTCQX MarketplaceRelated PostsAnavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s DiseaseJune 4, 2020Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)May 21, 2020 Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business UpdatesMay 7, 2020Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020May 5, 2020
Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s DiseaseJune 4, 2020
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)May 21, 2020
Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business UpdatesMay 7, 2020
Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020May 5, 2020
